ProMIS Neurosciences, Inc. carries no debt; cash flow comfortably covers obligations.

ProMIS Neurosciences, Inc.'s free cash flow has decreased 3.45% from $-27.18M last year to $-28.12M, signaling decreasing performance

ProMIS Neurosciences, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

ProMIS Neurosciences, Inc. has insufficient data to evaluate this check.

ProMIS Neurosciences, Inc. has a net cash position, so leverage is healthy.

ProMIS Neurosciences, Inc. carries no debt; interest obligations are fully covered.

ProMIS Neurosciences, Inc. has insufficient data to evaluate this check.

ProMIS Neurosciences, Inc.'s short-term liabilities of $10.41M exceed its short-term assets of $9.18M, signaling financial risk

ProMIS Neurosciences, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

ProMIS Neurosciences, Inc.'s return on equity of -237.99%, is lower than 15.00%, indicating bad performance

ProMIS Neurosciences, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

ProMIS Neurosciences, Inc. had positive net income in only 1 out of 5 years, indicating unstable earnings

ProMIS Neurosciences, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

ProMIS Neurosciences, Inc. has negative free cash flow, indicating cash burn

ProMIS Neurosciences, Inc.'s yearly earnings has decreased 1.53K% since last year from $2.78M to $-39.72M, signaling decreasing performance

ProMIS Neurosciences, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -68.02% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

ProMIS Neurosciences, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

ProMIS Neurosciences, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

ProMIS Neurosciences, Inc. had positive ROE in only 1 out of 5 years, indicating inconsistent returns on equity

ProMIS Neurosciences, Inc. has insufficient data to evaluate this check.

ProMIS Neurosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

ProMIS Neurosciences, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

ProMIS Neurosciences, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

ProMIS Neurosciences, Inc. has insufficient data to evaluate this check.

ProMIS Neurosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

ProMIS Neurosciences, Inc. has a price-to-book ratio of 1.58x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

ProMIS Neurosciences, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue